iZumi Bio, Inc., Appoints John Walker as Chief Executi... ( MOUNTAIN VIEW Calif. Feb. 12 /- i...)

iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer

Date:2/12/2009

MOUNTAIN VIEW, Calif., Feb. 12 /PRNewswire/ -- iZumi Bio, Inc., announced today the appointment of John P. Walker as Chief Executive Officer and a member of the company's Board of Directors. Walker was most recently the Chairman and CEO of Novacea, Inc. which merged with Transcept Pharmaceuticals Inc. in January 2009.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080806/AQW065LOGO)

iZumi Bio is focused on the development of induced pluripotent stem (iPS) cell technology to transform drug discovery and enable the promise of regenerative medicine.

"This is an exceptionally exciting time to be joining iZumi Bio, as we are seeing an increasing interest in the promise of stem cells to transform many aspects of the pharmaceutical industry," said Walker. "iZumi Bio has a leading position in industrializing the potential of iPS cells. Our goal is to create fully annotated, disease specific human cell lines that will fundamentally change the way in which small molecule drug discovery and development will be conducted in the future."

He continued, "Additionally, the development of these differentiated cell lines will enable the development of patient specific and cell replacement therapies."

Prior to joining Novacea, Walker, serving as a consultant and investor, was Executive Chairman and Principal Executive Officer of Renovis Inc.; Chairman and Interim CEO of Guava Technologies; KAI Pharmaceuticals and Centaur Pharmaceuticals; and Chairman and CEO of Bayhill Therapeutics. From 1993 to 2001, he was Chairman and CEO of Arris Pharmaceuticals and its successor corporation AXYS Pharmaceuticals Inc., and previously was Chairman and CEO of Vitaphore Corporation.

Walker began his career with American Hospital Supply Corporation, where he last served as President of the American Hosp
'/>"/>

SOURCE iZumi Bio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
3. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
4. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
5. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
6. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
9. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company

Post Your Comments:

(Date:12/15/2009)... 15 Reportlinker.com announces that a ... its catalogue: ,, The Future ... to 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The ... Future of Orphan Diseases Therapeutics - Market ...

(Date:12/15/2009)... Dec. 15 AstraZeneca (NYSE: ... Virginia (UVa) in Charlottesville, today announced that ... collaboration to enhance development of new treatments ... a secondary focus on peripheral vascular disease ... ,, The collaborative preclinical research projects will ...

(Date:12/15/2009)... PLYMOUTH, Minn., Dec. 15 The Mosaic Company (NYSE: ... quarter fiscal year 2010 earnings results and financial tables ... trading on the New York Stock Exchange. Results ... ,, The Company will host a conference call ... discuss the results. The call will begin at ...

(Date:12/15/2009)... -- The Center for Business Intelligence (CBI), ... to announce the full agenda for the ... Congress . The forum will take place ... 2010. ,, Over 1,500 senior-level Finance, Accounting, ... premier event since its inception, and this ...

[0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress

... 21 LeMaitre Vascular,Inc. (Nasdaq: LMAT ), ... acquired Biomateriali S.r.l., a privately held Italian,vascular graft ... assumption,of euro 0.8 million in intercompany liabilities, and ... The acquisition was structured as a stock,purchase., ...

... be Only Once-Yearly Implant for Prostate Cancer in ... Indevus Reaffirms Commitment to Prostate Cancer Patients, ... (Nasdaq: IDEV ) today commented on the ... their product,Viadur(R) (leuprolide acetate implant), which is indicated ...

... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... double-blind, placebo-controlled Phase 2a clinical,trial of MEM 3454, ... cognitive impairment associated with schizophrenia (CIAS). The,trial is ... effects,of three doses of MEM 3454 in patients ...

Other Biology Technology:LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 2 LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 3 Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R) 2 Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R) 3 Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2 Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3 Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4

LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

(Date:12/16/2009)... N.J., Dec. 9 BIO-key International, ... in finger-based biometric identification solutions, today announced ... most respected security publications, named BIO-key International ... the Access Control sub-category Biometrics. ,, (Logo: ... Peter Stephenson, technology editor, SC Magazine, "Biometric ...

(Date:12/16/2009)... 16 European Union (EU) member ... borders, which are increasingly subjected to unauthorised ... in advanced technology security and IT-based systems ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, New analysis ... Border Security Market Assessment - European ...

(Date:12/15/2009)... As soon as babies are born, they are susceptible ... For up to a month, their immune systems aren,t ... often minor, they can lead to serious problems if ... of Missouri researchers have pinpointed a group of depleted ... vaccine. , "We,re trying to improve the immune system ...

Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2 BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3 Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2 Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3 Researchers work on vaccine to improve immune system in newborns 2 Researchers identify new brain pathway for regulating weight and bone mass 10065 1 Researchers identify new brain pathway for regulating weight and bone mass 10065 2 Cambridge Healthtech Institute and Bio IT World Launch a New eNewsletter 3A Pharma Services News 58168 1 Cambridge Healthtech Institute and Bio IT World Launch a New eNewsletter 3A Pharma Services News 58168 2 5th Annual Stem Cell Summit Set for Feb 16 in New York City 58163 1 5th Annual Stem Cell Summit Set for Feb 16 in New York City 58163 2 5th Annual Stem Cell Summit Set for Feb 16 in New York City 58163 3

[0] BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine [0] Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan [0] Researchers work on vaccine to improve immune system in newborns

... a type of blue-green algae known as Nostoc, shows promise ... other neurodegenerative diseases, according to an in vitro study by ... time that a potent agent against Alzheimer's has been isolated ... published in the Dec. 26 issue of the Journal ...

... been used to track the source of illegal drugs, ... some new uses: detecting rapidly growing cancers and studying ... "stable isotope ratio mass spectrometry," can determine where a ... of an element in the substance ?such as the ...

... Institute for Biomedical Research have successfully demonstrated that ... is indeed possible, at least in mice. ... (ANT), proposes that researchers first create genetically altered ... uterus, and then extract stem cells from these ...

Other Biology News:Natural compound from 'pond scum' shows potential activity against Alzheimer's 2 War on terror meets war on cancer 2 War on terror meets war on cancer 3 War on terror meets war on cancer 4 War on terror meets war on cancer 5 War on terror meets war on cancer 6 Researchers offer proof-of-concept for Altered Nuclear Transfer 2 Researchers offer proof-of-concept for Altered Nuclear Transfer 3

Natural compound from 'pond scum' shows potential activity against Alzheimer's War on terror meets war on cancer Researchers offer proof-of-concept for Altered Nuclear Transfer

One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....

[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...

...

One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....

Biology Products:

Hemoglobin Colorimetric Assay Kit, QuantiChrom from BioAssay Systems Prostaglandin D2 , 5,6,8,9,12,14,15(n)-3H Conjugated/Tagged from GE Healthcare, formerly Amersham Biosciences 10% Normal Rabbit Serum from Invitrogen QuantiChrom™ Sulfate Assay Kit from BioAssay Systems

iZumi Bio, Inc., Appoints John Walker as Chief Executi...( MOUNTAIN VIEW Calif. Feb. 12 /- i...)